Compare UTHR & SW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UTHR | SW |
|---|---|---|
| Founded | 1996 | 1934 |
| Country | United States | Ireland |
| Employees | N/A | 97000 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.8B | 20.3B |
| IPO Year | 1999 | N/A |
| Metric | UTHR | SW |
|---|---|---|
| Price | $579.93 | $42.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 12 |
| Target Price | ★ $561.57 | $54.08 |
| AVG Volume (30 Days) | 612.6K | ★ 5.0M |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 4.28% |
| EPS Growth | ★ 13.07 | N/A |
| EPS | ★ 27.86 | N/A |
| Revenue | ★ $1,483,300,000.00 | N/A |
| Revenue This Year | $7.08 | $4.50 |
| Revenue Next Year | $14.32 | $3.10 |
| P/E Ratio | ★ $20.89 | $38.98 |
| Revenue Growth | ★ 2.38 | N/A |
| 52 Week Low | $272.18 | $32.73 |
| 52 Week High | $607.89 | $52.65 |
| Indicator | UTHR | SW |
|---|---|---|
| Relative Strength Index (RSI) | 62.75 | 54.48 |
| Support Level | $464.92 | $41.24 |
| Resistance Level | $607.89 | $44.38 |
| Average True Range (ATR) | 18.49 | 1.31 |
| MACD | 1.72 | 0.51 |
| Stochastic Oscillator | 69.09 | 95.54 |
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
Smurfit WestRock PLC manufactures corrugated packaging and consumer packaging, such as folding cartons and paperboard. operates a vertically integrated system supplying wood and recovered fiber to produce various grades of board, which are then converted into packaging products. Its main packaging categories include corrugated containers and consumer packaging, with additional products such as solidboard, kraft paper, graphic board, paper sacks, and bag-in-box packaging. The company's geographical segments include North America (including the U.S., Canada and Mexico), Europe, the Middle East and Africa and Asia-Pacific, and Latin America. The majority of the company's revenue is derived from product sales in the North American region.